<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Targeting the FGF/FGFR Signaling Axis with PDX Models

fgf and fgfr oncogenic signaling mechanisms

fgf and fgfr oncogenic signaling mechanismsDiscover the complex range of FGFR family aberrations in cancer and how PDX models are a powerful tool for assessing new FGFR-targeted therapeutic options.

The Multiple Pathways Involved in Cancer Development

Aberrant receptor tyrosine kinase signaling leads to hyperactivation downstream of many pathways implicated in oncogenesis. One of these is the RAS pathway; we’ve previously discussed why mutations in RAS family genes are important in cancer development and how to target this therapeutically.

Another affected pathway centers around the fibroblast growth factor receptor (FGFR) which is frequently altered in human cancer. Deregulation of the fibroblast growth factor (FGF)/FGFR signaling axis is implicated in oncogenesis, tumor progression, and resistance to anticancer therapy across many tumor types.

FGFR Family

There are four FGFR family members, FGFR1 through FGFR4, which play roles in regulating cell growth, proliferation, differentiation, wound healing, and formation of blood vessels.

FGFR activation by FGF leads to phosphorylation of specific tyrosine residues. This initiates a cascade of intracellular events activating the major survival and proliferative signaling pathways RAS-MAPK, PI3K-AKT, PLCγ, and STAT.

FGFR Aberrations in Cancer

An extensive review of the range of FGFR aberrations found across different cancer types has been performed, with over 4,850 tumors analyzed by Next-Generation Sequencing (NSG).

Overall, 7% of the tumors tested had FGFR aberrations, split proportionally as:

  • FGFR1 - 49%
  • FGFR2 - 19%
  • FGFR3 - 23%
  • FGFR4 - 7%

Gene amplifications provided the majority of the FGFR aberrations (66%), followed by mutations (26%) and rearrangements (8%).

Almost every cancer type showed some tumors with FGFR aberrations. Higher frequencies were observed in urothelial cancer (32%), breast cancer (18%), endometrial cancer (∼13%), squamous lung cancers (∼13%), and ovarian cancer (∼9%).

FGFR Amplifications

FGFR1 amplifications (8p12 locus) are found in approximately 15% of squamous non-small cell lung cancers (NSCLC) and 10% of breast cancers (predominantly in hormone receptor positive disease). They are also observed to a lesser extent in ovarian, bladder, renal cell carcinoma, and rhabdomyosarcoma.

FGFR2 amplification is seen less often than FGFR1 amplification, but has been observed in around 8% of gastric cancers and 2% of breast cancers.

Amplification of FGFR3 and FGFR4 is not frequently reported, with activation of these receptors often linked to somatic mutation.

FGFR Mutations

Somatic activating FGFR point mutations have been identified, resulting in multiple aberrant signaling mechanisms. Most of these mutations are frequently observed outside the kinase domain, which is in opposition to other tyrosine kinase receptors (e.g. EGFR). Mutations in FGFR2 and FGFR3 are the more frequent with rare mutations observed for FGFR1.

FGFR2 mutations, consisting mainly of missense activating mutations (S252W, P253R), are found in around 12% of endometrial cancer, with lower proportions seen in NSCLC, gastric, and urothelial cancer.

FGFR3 mutations occur in the transmembrane (G370C, Y373C) or extracellular (R248C, S249C) domains, resulting in enhanced activation and increased receptor dimerization.

FGFR3 mutations are found in around 75% of invasive urothelial cell carcinomas, 15% of high-grade invasive urothelial cancers, and around 5% of cervical cancers.

Finally, FGFR4 mutations (K535, E550) present in the kinase domain and which induce autophosphorylation of the receptor are found in 7% of rhabdomyosarcoma.

In addition to somatic activating mutations, FGFR germline single-nucleotide polymorphisms (SNPs) have been identified with an increased cancer risk or a poor prognosis.

FGFR Gene Fusions

Gene fusions are the result of translocation, interstitial deletion, or chromosomal inversion. FGFR gene fusions occur at a low incidence, with fusions involving FGFR2 and FGFR3 the most common.

The discovery of the first recurrent FGFR fusion, FGFR3-TACC3, was observed in high-grade brain tumors (i.e. glioblastoma), followed by bladder and, in some cases, lung cancer.

FGFR1 fusions although non-recurrent (i.e. ZNF198, BCR, FOP) have been observed mostly in myeloproliferative disorder stem cell leukaemia/lymphoma syndrome (SCLL/8p11 myeloproliferative syndrome) but also in in lung squamous cell carcinoma (LUSC), breast cancer, glioblastoma and low-grade brain tumors.

FGFR2 fusions (i.e. CIT, CCDC6, CCAR2, OFD1, BICC1, etc.) are found in 15% of intrahepatic cholangiocarcinoma and on rare occasions in thyroid, lung, and prostate cancers.

Deregulation of Autocrine/Paracrine Loops

In addition to genetic abnormalities which lead to ligand-independent signaling and constitutive receptor activation, ligand-dependent signaling involving FGFs and FGFRs can also be deregulated.

Deregulation of FGF expression and secretion in cancer or stromal cells contributes to, or drives, carcinogenesis. Preclinically, genetically engineered mouse (GEM) models using the mouse mammary tumor virus (MMTV) have been described to have increased expression of FGF8, FGF4, and FGF3 in induced mammary gland tumors.

More recently, multiple FGFs have been described in various cancers including breast, prostate, colorectal cancers, hepatocellular carcinoma, and NSCLC.

Targeting the FGFR Family Therapeutically

In light of the many alterations in the FGF/FGFR pathways, multiple therapeutic strategies have been developed or are in development. These strategies use non-selective and selective FGFR tyrosine kinase inhibitors (TKIs), antagonist antibodies, or FGF ligand traps.

Non-selective FGFR TKIs (e.g. dovitinib, lenvatinib, lucitanib, nintedanib) bind to the ATP-binding domain of the catalytic site of the receptor, but can also target other RTKs (i.e. VEGFR and PDGFR).

In order to increase specificity, and reduce the toxicity associated with multitargeting TKIs, selective FGFR inhibitors have been developed including compounds like AZD4547, NVP-BGJ398, JNJ-42756493, LY2874455, TAS120, and Debio-1347.

Several monoclonal antibodies targeting either FGF/FGFR are in preclinical or early phase development. These antibodies block FGFR signaling by interfering with ligand binding or receptor dimerization and include antiFGFR3 (MGFR1877S), anti-FGFR2-IIIb (GP369, FPA144), and anti-FGFR2 (BAY1187982).

The final strategy is to prevent FGF ligand binding to FGFR. The soluble fusion protein FP-1039 (GSK3052230) consists of the extracellular domain of FGFR1c fused to the Fc region of IgG1 preventing FGF1, FGF2, and FGF4 binding. A Phase IB trial has been completed evaluating FP-1039 in association with chemotherapy in patients with lung cancer (NCT01868022).

Evaluating FGFR-Targeted Therapies Preclinically with PDX Models

While multiple strategies are being developed, clinical response has so far been limited. In order to better evaluate the different FGFR-targeted therapeutic strategies, improved preclinical models are needed. More predictive models which fully capture the complex interplay and mechanism of the different FGFR clinical aberrations are required.

Patient-derived xenografts (PDX), which are highly clinically-relevant preclinical models recapitulating human disease, provide a powerful approach. Models are available featuring clinically relevant FGFR aberrations (such as FGFR3 fusions, including FGFR3-TACC3). Databases collating PDX NGS data also allow the search and selection of models featuring rare FGFR fusions or mutation which may be hard to find in traditional CDX models.

Numerous publications have demonstrated the use of PDX to investigate FGFR targeted therapies in different indications, such as cholangiocarcinoma, endometrial, NSCLC, gastric and HCC cancer.

Mouse Clinical Trials

Large panels of PDX models can also be used in Mouse Clinical Trials, which mimic a patient Phase II trial. Each PDX subject reflects the pathology of its original patient, behaving as a patient avatar, and the cohort of patient avatars represents a diversity of the human patient population. This can allow testing of an agent across a population of FGFR mutated/fused disease, and to assess how different aberrations affect response.

As well as studying response to a drug across a population, another main use of PDX Mouse Clinical Trials is to identify predictive biomarkers. This has already been accomplished for dovitinib in lung squamous cell carcinoma (LSCC), showing that overexpression of gene sets associated with FGFR pathway activation could be a potential biomarker for FGFR inhibition in LSCC patients.

Summary

The FGF/FGFR signaling pathway is complex, with multiple alterations and heterogenous behaviors across a variety of cancer types. Currently, there are multiple FGFR inhibitors in development, which so far have had limited clinical response.

More clinically-relevant and predictive preclinical models, such as PDX, are required for preclinical testing. This will allow us to have a deeper understanding of the mechanisms at play, and to improve evaluation of new agents and combination therapies to overcome the currently limited efficacy. New models can also help to identify further predictive biomarkers.


Related Posts